AbbVie (ABBV) has submitted applications to the US FDA and the European Medicines Agency seeking an additional indication of vitiligo, a condition where skin loses its pigment, for Rinvoq (upadacitinib).
The application is supported by a pair of phase 3 trials that both met co-primary endpoints measured by the Total Vitiligo Area Scoring Index and the Facial Vitiligo Area Scoring Index, which indicate vitiligo improvement from baseline.
AbbVie noted that if approved, Rinvoq will become the first systemic treatment for those with the condition.
